Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)
Fulcrum Therapeutics' (FULC) quarterly FCF Margin came in at 73.64% in Q2 2024, up 242148.0% year-on-year from N/an in Q3 2023, and up 102.71% on a QoQ basis from 2717.11% in Q4 2023.
Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of FCF Margin data on file, last reported at 73.64% in Q2 2024.
- On a quarterly basis, FCF Margin rose 242148.0% year-over-year to 73.64% in Q2 2024; TTM through Jun 2025 was 81.46%, a 6562.0% decrease from a year earlier, with the FY2024 full-year figure at 3.12%, up 325795.0% from the prior year.
- FCF Margin for Q2 2024 stood at 73.64%, up from 2717.11% in the prior quarter.
- Over the last five years, FCF Margin for FULC reached as high as 73.64% in Q2 2024 and fell as low as 8232.88% in Q1 2023.
- Historically, FCF Margin has averaged 1703.32% across 5 years, with a median of 862.35% in 2022.
- Across the five-year window, FCF Margin plunged 737054 bps in 2023 and jumped 242148 bps in 2024, its largest moves.
- Year by year, FCF Margin stood at 480.43% in 2020, then increased by 8 bps to 442.41% in 2021, then slumped by 550 bps to 2876.2% in 2022, then advanced by 6 bps to 2717.11% in 2023, then jumped by 103 bps to 73.64% in 2024.
- Per Business Quant data, the three most recent FCF Margin figures were 73.64% in Q2 2024, 2717.11% in Q4 2023, and 3011.73% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 73.64% |
| Dec 31, 2023 | -2,717.11% |
| Sep 30, 2023 | -3,011.73% |
| Jun 30, 2023 | -2,347.84% |
| Mar 31, 2023 | -8,232.88% |
| Dec 31, 2022 | -2,876.20% |
| Sep 30, 2022 | -2,345.82% |
| Jun 30, 2022 | -1,449.04% |
| Mar 31, 2022 | -862.35% |
| Dec 31, 2021 | -442.41% |
| Sep 30, 2021 | -480.41% |
| Jun 30, 2021 | -402.15% |
| Mar 31, 2021 | -344.29% |
| Dec 31, 2020 | -480.43% |
| Sep 30, 2020 | -287.88% |
| Jun 30, 2020 | -700.60% |
| Mar 31, 2020 | -2,048.93% |